β Back to the plain-language case
Abstract's $1.3 billion TB cost total exceeds the paper's own yearly costs about tenfold
Lancet Reg Health Am (2024) Β· doi:10.1016/j.lana.2024.100905 Β· PMC11747192
Summary
The Abstract (Findings) and the Discussion give the total direct cost of pulmonary TB to Brazil's public health system over 2015β2022 as more than, or about, $1.3 billion. The Results give the same total as 108 million dollars, with yearly costs between 9.98 million (2022) and 21.38 million (2017) dollars; eight such years can add up to at most $171 million, so $1.3 billion is impossible on the paper's own numbers. The authors' public data file reproduces the yearly values exactly and sums to $131.3 million (all records) or $124.6 million (the 426,040 analysed cases); $1.3 billion is about ten times either. The figure is the abstract's headline estimate of the economic burden, and no correction has been published.
What the paper reports
Abstract, Findings:
The total direct cost for pulmonary TB in Brazil during the seven years exceeded $1.3 billion, with retreatment cases accounting for $23.5 million.
Discussion, second paragraph:
The total TB cost to the public health system over the last seven years amounted to approximately $1.3 billion. While costs varied according to each population, attention is drawn to the expenditure on retreatment cases, totalling $23.5 million.
Results, "Evaluating the direct cost of pulmonary TB from 2015 to 2022":
The overall cost of pulmonary TB treatment in Brazil exhibited variations over the years, reaching its highest value in 2017 (21.38 million dollars) and the lowest in 2022 (9.98 million dollars), accumulating to a total cost of 108 million dollars spent over the 7-year period (Fig. 2a). Further stratifying the cost based on the history of anti-TB treatment, surprisingly, despite fluctuations in the total cost and the cost of new cases, the cost of retreatment cases remained stable over the years with an accumulated total of 23,5.million dollars (Fig. 2b).
Methods, "Tuberculosis direct cost analysis", on how the total is built:
After calculating the cost per case, we summed the value of each case for each year of the study.
Results, "Characteristics of the study participants":
Following these exclusions, our study comprised a total of 426,040 pulmonary TB cases.
Results, cost needed to reach a 90% cure rate:
Initially, an investment of $ 275 was identified as necessary for the overall population to achieve a 90% cure rate. Further delineating the groups based on treatment history, the new case subgroup required a similar investment of $276 to attain the 90% cure rate, mirroring the overall population. However, the retreatment group necessitated increased efforts, with an investment of $318 for the same target (Fig. 6).
The per-group investments elsewhere in the Results run from $217 (health workers) to $366 (homeless). Table 1 has columns headed N = 345,908 (new cases) and N = 80,132 (retreatment).
What the paper's own numbers show
Method. The Methods define the total as the sum of per-case costs, added up by year. The Results give the largest and smallest yearly totals, which bound any total over the study period: 2015β2022 spans eight calendar years (the paper says seven), so the total must lie between 8 Γ 9.98 and 8 Γ 21.38 million dollars. I then checked the total against the paper's case counts and its per-case costs. Finally, I summed the per-case cost column (ind_cost) of the data file the paper links in its Data sharing statement (data/SINAN_TB.parquet in the authors' public repository, commit 6e74aaf of 2024-09-09, SHA-256 checked), following the authors' own code (scripts/Main_code.Rmd), which builds Fig. 2a as the sum of ind_cost by year over all records. Every number below is printed by recompute.py.txt.
| Quantity | Location | Reported | Recomputed |
|---|---|---|---|
| Total direct cost, 2015β2022 | Abstract (Findings); Discussion | "exceeded $1.3 billion"; "approximately $1.3 billion" | Not possible: at most $171.0M from the stated yearly maximum |
| Total direct cost, 2015β2022 | Results (Fig. 2a) | 108 million dollars | Within the bounds: $69.9Mβ$149.7M (7 years), $79.8Mβ$171.0M (8 years) |
| Ratio of the two totals | Abstract vs Results | $1.3B vs $108M | 12.04Γ |
| Years at the 2017 maximum needed to reach $1.3B | Results | 7-year period | 60.8 years |
| Cost per analysed case (426,040) | Results, Fig. 1 | not given | $253 if $108M; $3,051 if $1.3B |
| Paper's modelled cost per case for 90% cure | Results, Figs 6β7 | $217β$366 (overall $275) | $1.3B per case is 8.3Γ the highest |
| $1.3B spread over all 743,823 notified TB cases | Results | not given | $1,748 per case |
| Retreatment ($23.5M) as share of total | Abstract; Results; Table 1 | $23.5M | 21.8% of $108M (retreatment is 18.8% of cases); 1.8% of $1.3B |
| Implied cost per new case vs per retreatment case | Table 1 counts | retreatment needs more ($318 vs $276) | $244 vs $293 if $108M; $3,690 vs $293 if $1.3B |
| Yearly totals, authors' data (million USD) | Fig. 2a; Results | 21.38 (2017), 9.98 (2022) | 13.98, 16.48, 21.38, 20.81, 20.06, 14.02, 14.60, 9.99 (2015β2022) |
| Total, authors' data, all 458,297 records | Fig. 2a | 108 million dollars | $131.3M |
| Total, authors' data, 426,040 analysed cases | Results; Table 1 | β | $124.6M (row counts 345,908 new and 80,132 retreatment match Table 1) |
| New cases only, authors' data, all records | Fig. 2b | β | $107.8M |
| Retreatment only, authors' data, all records | Results; Fig. 2b | 23,5 million dollars | $23.6M |
| Highest cost of any single case | authors' data | β | $490.24; 426,040 cases at that cost = $208.9M |
| $1.3B / data total | β | β | 9.90Γ (all records); 10.44Γ (analysed cases) |
| Data total in BRL, year by year at Table S3 rates | Supplementary Table S3 | β | R$530M (0.53B BRL) |
Every check in the paper's own text and data points to a total of roughly $100β$130 million. The $1.3 billion in the Abstract and Discussion is about 12 times the Results figure and about 10 times what the authors' data add up to.
A second, smaller point appears in the data. The Results call 108 million dollars the overall total, but the authors' data and the yearly values plotted in Fig. 2a sum to $131.3 million. $108 million matches the new-case subtotal ($107.8 million), and $107.8M + $23.6M (retreatment) = $131.3M. The Results total therefore appears to leave out retreatment cases. This does not change the main finding: every candidate total lies between about $108 and $131 million.
Figure
Figure 1. The two statements of the same quantity, the total direct cost of pulmonary TB over 2015β2022. Left: the Abstract (Findings) and Discussion, $1,300 million. Right: the Results, which give the yearly maximum and minimum and a total of $108 million; the two differ by a factor of 12. Orange marks values printed in the paper. The blue lines below are recomputed by recompute.py.txt: the range an eight-year total can take given the stated yearly extremes, and the totals of the authors' public data.
Figure 2. The same totals on one linear axis that starts at zero, in million US$. Orange dots: values reported in the paper (Abstract and Discussion, 1,300; Results, 108). Blue: recomputed values (the range 80β171 allowed by the stated yearly maximum and minimum over eight years; the authors' data summed over all records, 131, over the 426,040 analysed cases, 125, and over new cases only, 108). Only the Abstract value lies outside the range the paper's own yearly figures allow.
Why it matters
- It is the paper's headline economic result. The total direct cost opens the Abstract's Findings and the Discussion's report of results. It is the number most likely to be quoted in citing papers, policy documents and budget discussions, and the paper presents itself as the first national estimate of this cost for Brazil.
- The overstatement is about tenfold. A reader of the Abstract would take the seven-year cost to the public health system as more than $1.3 billion (about $160β185 million a year). The paper's own Results and data give about $108β131 million in total, roughly $14β19 million a year, or about $250β$290 per case.
- It distorts the retreatment share. Read against $1.3 billion, the $23.5 million spent on retreatment cases looks like about 2% of spending. Against the data total it is about 18β22%, close to the 18.8% share of cases that are retreatments. The paper singles out retreatment spending in both the Abstract and the Discussion.
- Other results are not affected. The number-needed-to-treat estimates for directly observed treatment, the per-case investments needed to reach a 90% cure rate ($217β$366), and the yearly pattern in Fig. 2 come from per-case costs and models, not from the overall total, and they agree with the data.
Explanations considered
- A different currency. Not supported. The Methods convert costs from Brazilian reais to US dollars using yearly rates (Supplementary Table S3: 3.19β5.40 BRL per USD), and all reported values carry a dollar sign. $108 million is R$0.34β0.58 billion at those rates, and the authors' data total converted year by year is R$0.53 billion. Neither gives 1.3 billion. The authors' Portuguese abstract (Supplementary mmc2) also reads "excedeu US$ 1,3 bilhΓ£o", in dollars.
- A wider population. Not supported. Spread over all 743,823 TB notifications in 2015β2022, including those the study excluded, $1.3 billion is still $1,748 per case. That is about 5β8 times every per-case cost in the paper. In the authors' data the most expensive single case costs $490.24; even if all 426,040 analysed cases cost that much, the total would be $208.9 million.
- A broader definition of cost. Not supported. The Limitations say the analysis is "omitting costs related to hospitalization, maintenance of health unit infrastructure, indirect costs such as productivity loss, undiagnosed cases, death, patient expenses, and the broader societal impact". The paper offers no wider cost measure that could produce $1.3 billion.
- The length of the period. Not supported. 2015β2022 spans eight calendar years, although the paper says seven, but eight years at the 2017 maximum still come to only $171 million. Reaching $1.3 billion would take 60.8 years at that rate.
- A per-case or cumulative figure misread. Not supported. The Methods describe the total as the sum of per-case costs by year, and Fig. 2a is described as "the cumulative economic burden over the seven years". The yearly values in the Results and the data are already cumulative within each year.
- A typographical slip in the Results rather than the Abstract. Not supported. The yearly maximum and minimum in the Results, the yearly sums in the authors' data, the retreatment share and the per-case costs all agree with a total of about $108β131 million. Only the Abstract and Discussion figure disagrees with them. An earlier conference abstract of this study (MEDTROP 2024) states that the total "exceeded $108 million". The leading digits of $1.3 billion match the data total of $131 million, which would fit a misplaced decimal point, but the paper gives no basis for deciding how the figure arose.
Status
- Version of record. The publisher pages (thelancet.com and sciencedirect.com, pii S2667193X24002321) returned HTTP 403. The version of record was read on the live PMC page and in the publisher full-text XML served by Europe PMC; both contain "$1.3 billion" in the Abstract Findings and the Discussion and "108 million dollars" in the Results, identical to the archived text quoted above. This is not a conversion artefact.
- Supplements. Europe PMC supplementary files checked: mmc1.docx (Supplementary Methods, Figs S1βS6, Tables S1βS5) and mmc2.docx (Portuguese abstract). The Supplementary Methods state that the per-case costs were summed by year "and then summed the years to obtain the total economic cost or burden"; no supplementary table gives an overall total. The Portuguese abstract repeats "US$ 1,3 bilhΓ£o".
- Data and code. The authors' public repository (linked in the paper) holds
data/SINAN_TB.parquet(458,297 records, committed 2024-09-09) andscripts/Main_code.Rmd. Summing itsind_costcolumn by year reproduces the yearly values in the Results. - Corrections and comments. No erratum, correction or retraction notice was found on Crossref, PMC or Europe PMC. PubPeer's search page and API returned a human-verification block and could not be queried directly; a web search found no PubPeer thread or published correction for this article.
- Sources. PMC11747192; Europe PMC full-text XML; authors' data and code at the GitHub address given in the paper's Data sharing statement (commit 6e74aaf); MEDTROP 2024 conference abstract.
- As of 2026-10-24.
Suggested correction
In the Abstract (Findings) and the Discussion (second paragraph), the total direct cost should be replaced by the total from the study's data. The authors should confirm which population the headline total covers. Summed over all records, as in Fig. 2a, it is about $131 million; over the 426,040 analysed cases it is about $125 million. For example: "The total direct cost for pulmonary TB in Brazil during 2015β2022 was approximately $131 million, with retreatment cases accounting for $23.5 million." The same figure should replace "approximately $1.3 billion" in the Discussion. The Results sentence giving "a total cost of 108 million dollars" should be checked as well, since $108 million matches the new-case subtotal rather than the overall total shown in Fig. 2a. "23,5.million" should read "23.5 million". The authors may also wish to say "eight years" (2015β2022) instead of "seven years" in the title, Abstract, Results and Discussion.